Li Chao, Zhang Jian, Wang Hui
Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China.
Universal Medical Imaging Diagnostic Center, Shanghai 201103, P.R. China.
Oncol Lett. 2019 Aug;18(2):1641-1648. doi: 10.3892/ol.2019.10500. Epub 2019 Jun 19.
The aim of the present study was to predict the prognostic value of F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in the metastatic lymph nodes (mLNs) of patients with papillary thyroid carcinoma (PTC) with a negative iodine-131 (I) whole-body scan (WBS). The present retrospective study included 32 patients with PTC undergoing standard surgery and radioiodine treatment. All patients received F-FDG PET/CT imaging prior to and following therapy. All mLNs were divided into an effective treatment group (group A) and ineffective treatment group (group B) based on the PET Response Criteria in Solid Tumors 1.0 guidelines. All the patients were followed up for ≥9 months. A significant difference was identified in the peak standardized uptake value (SULpeak) between group B (7.85±3.20) and group A (5.36±2.19). A cut-off value of 5.85 was used to distinguish ineffective treatment of lesions from mLNs receiving radioactive ablation based on receiver operating characteristic (ROC) curve analysis with an area under the ROC curve of 0.755. Patients with a high SULpeak (P=0.003) and extrathyroidal extension (P=0.030), confirmed by pathology, more frequently exhibited a poor prognosis. In conclusion, tracer uptake of F-FDG for cervical metastatic nodes was revealed as a predictor for the clinical outcome of patients with PTC treated with radioiodine therapy. The present results also indicated that high SULpeak and extrathyroidal extension are poor predictors for patients with mLNs receiving I therapy.
本研究的目的是预测氟脱氧葡萄糖(FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)在碘-131(I)全身扫描(WBS)阴性的乳头状甲状腺癌(PTC)患者转移性淋巴结(mLNs)中的预后价值。本回顾性研究纳入了32例接受标准手术和放射性碘治疗的PTC患者。所有患者在治疗前后均接受了F-FDG PET/CT成像。根据实体瘤PET反应标准1.0指南,将所有mLNs分为有效治疗组(A组)和无效治疗组(B组)。所有患者均随访≥9个月。B组(7.85±3.20)和A组(5.